Multiple Sclerosis Trial, Recruiting NCT07360886 Sponsor: University Hospital Olomouc Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Multiple Sclerosis Trial, Recruiting

NCT07360886
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have agreed to take part by signing a consent form.
  • You have been diagnosed with a relevant neurological condition that meets the trial's specific diagnostic requirements.
  • You hold a valid driver's license and have proof that you are currently an active driver.
  • You are between 18 and 85 years old.

Who may not be able to join:

  • You have been diagnosed with dementia, confirmed by a recent psychological test (specifically a memory and thinking test where you scored 24 points or below).
  • You have a medical condition that, under Czech law, prevents or seriously limits your ability to drive safely — for example, dementia, epilepsy, or severe problems with consciousness.
  • You are younger than 18 or older than 85 years of age.
  • If you are in the Multiple Sclerosis (MS) group: you have had a confirmed and treated MS relapse (a flare-up of symptoms) within the last 6 weeks before joining the study.
  • If you are in the MS group: your current disability score (a standard MS severity scale) is above 6.5, indicating significant physical limitation (confirm with trial site).
  • If you are in the Parkinson's Disease (PD) group: your current score on a standard Parkinson's severity scale is 4 or higher, indicating more advanced disease (confirm with trial site).
  • For both groups: there is laboratory evidence that your condition has recently worsened due to an infection-related cause.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +420 702 048 036

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University Hospital Olomouc
Registry
ClinicalTrials.gov
Start date
1 November 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇿 Czechia

Primary endpoints

Vienna Test Systems (VTS) - Determination Test (DT); Vienna Test Systems (VTS) - Reaction Test (RT); Vienna Test Systems (VTS) - Response inhibition (INHIB); Vienna Test Systems (VTS) - Vigilance/Sustained attention (WAFV) - Short version

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov